Nanogen weighs alternatives to Elitech merger
This article was originally published in The Gray Sheet
Executive Summary
San Diego-based molecular diagnostics firm Nanogen says it is investigating alternatives to its pending stock-swap merger with private French diagnostics firm Elitech. Announced last August, the merger would provide Elitech shareholders with about $86 million worth of Nanogen stock - resulting in Elitech investors holding up to 68.7% of the combined company's shares upon completion of the deal. Both firms "believe it is unlikely that Nanogen will have obtained stockholder approval or that, given the current financial market conditions, the companies will have arranged for working capital financing by March 31, 2009, both of which are closing conditions" of the merger pact, Nanogen explains Jan. 21. Options include a restructuring of the original Elitech agreement
You may also be interested in...
Nanogen asset sale to Elitech subject to court approval
Delaware bankruptcy court will review molecular and rapid diagnostic product maker Nanogen's recent chapter 11 filing and a proposed sale of the firm's assets to private French diagnostics firm Elitech for $25.7 million, Nanogen announces May 14. The asset sale will be subject to a court-supervised auction in which interested parties may submit better offers. Nanogen and Elitech initially had planned a stock-swap merger, but San Diego-based Nanogen was unable to secure working capital (1"The Gray Sheet" Feb. 2, 2009, In Brief)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.